Table 1 Sociodemographic and clinical characteristics of the patients
From: The benefits of psychosocial interventions for cancer patients undergoing radiotherapy
Characteristic | Total n = 178(%) | IG n = 89(%) | CON n = 89(%) | p value |
|---|---|---|---|---|
Sex | Â | Â | Â | Â |
  Male | 75(42%) | 38(43%) | 37(42%) | 0.879 |
  Female | 103(58%) | 51(57%) | 52(58%) | |
Age (years) | Â | Â | Â | Â |
  20-49 | 113(63%) | 56(63%) | 57(64%) | 0.585 |
  50-69 | 64(36%) | 33(37%) | 31(35%) | |
  70-79 | 1(1%) | 0 | 1(1%) | |
Marital status | Â | Â | Â | Â |
  Married | 172(97%) | 87(98%) | 85(96%) | 0.406 |
  Single/divorced/widow | 6(3%) | 2(2%) | 4(4%) | |
Education level | Â | Â | Â | Â |
  Primary school | 5(3%) | 2(2%) | 3(3%) | 0.808 |
  Junior high school | 18(10%) | 8(9%) | 10(11%) | |
  Senior high school | 86(48%) | 46(52%) | 40(45%) | |
  Above college | 69(39%) | 33(37%) | 36(41%) | |
Employment status | Â | Â | Â | Â |
  Employed | 131(73%) | 67(75%) | 64(72%) | 0.707 |
  Resigned | 19(11%) | 10(11%) | 9(10%) | |
  Unemployed | 28(16%) | 12(13%) | 16(18%) | |
Locality | Â | Â | Â | Â |
  Urban | 78(44%) | 40(45%) | 38(43%) | 0.763 |
  Rural | 100(56%) | 49(55%) | 51(57%) | |
Primary cancer site | Â | Â | Â | Â |
  Nasopharyngeal | 62(35%) | 31(35%) | 31(35%) | 0.989 |
  Breast | 41(23%) | 19(21%) | 22(25%) | |
  Gynecological cancer (cervical and endometrial) | 31(17%) | 14(16%) | 17(19%) | |
  Lung | 14(7%) | 7(8%) | 7(8%) | |
  Others (rectum\lymphoma\glioma etc.) | 30(17%) | 15(17%) | 15(17%) | |
ECOG performance status | Â | Â | Â | Â |
  0 ~ 1 | 170(96%) | 86(97%) | 84(94%) | 0.469 |
  2 | 8(4%) | 3(3%) | 5(6%) | |
Disease progression | Â | Â | Â | Â |
  Advanced | 111(62%) | 53(60%) | 58(65%) | 0.439 |
  Early stage | 67(38%) | 36(40%) | 31(35%) | |
History of operation | Â | Â | Â | Â |
  Yes | 87(49%) | 44(49%) | 43(48%) | 0.881 |
  No | 91(51%) | 45(51%) | 46(52%) | |
Radiotherapy dose | Â | Â | Â | Â |
  ≥70Gy | 78(44%) | 39(44%) | 39(44%) | 0.894 |
  50 ~ 70Gy | 97(54%) | 49(55%) | 48(54%) | |
  <50Gy | 3(1%) | 1(1%) | 2(2%) | |
Brachytherapy | 14(7%) | 6(7%) | 8(9%) | |
Chemotherapy | Â | Â | Â | Â |
  None | 52(29%) | 29(33%) | 23(26%) | 0.710 |
  Neoadjuvant | 13(7%) | 6(7%) | 7(8%) | |
  Concomitant | 77(43%) | 35(39%) | 42(47%) | |
  Adjuvant | 102(57%) | 50(56%) | 52(58%) | |
Comorbid condition | Â | Â | Â | Â |
  None | 158(89%) | 77(87%) | 81(91%) | 0.877 |
  Diabetes | 7(4%) | 4(4%) | 3(3%) |  |
  Hypertension | 14(8%) | 8(9%) | 6(7%) |  |
  Coronary heart disease | 3(2%) | 1(1%) | 2(2%) |  |
  Hepatitis B | 3(2%) | 2(2%) | 1(1%) |  |